GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nimacimab   Click here for help

GtoPdb Ligand ID: 14321

Synonyms: JNJ 2463 | JNJ-2463 | RYI-018 | RYI018
Compound class: Antibody
Comment: Nimacimab (RYI-018; Skye Bioscience) is a humanized IgG4 anti-cannabinoid receptor 1 (CB1) monoclonal antibody. It acts to inhibit receptor function and is peripherally restricted.
Based on peptide sequence matches for antibody heavy and light chains between the INN record and patent US10308712B2, nimacimab appears to be clone PIC4-H2-IgG4 therein [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Nimacimab (RYI-018) was progressed to clinical evaluation to determine safety and efficacy, for the treatment of metabolic health disorders including obesity and metabolic dysfunction-associated steatohepatitis (MASH). An October 2025 press release stated that nimacimab failed to induce weight loss as a monotherapy in obese trial participants [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03261739 Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) Phase 1 Interventional Bird Rock Bio, Inc.